HLA-B*57:01 Genotype, Abacavir Sensitivity
Abacavir sulfate is an antiretroviral drug used for the treatment of HIV. It is generally well tolerated; however, <10% of patients may experience hypersensitivity which can be severe and, in some cases, fatal. The symptoms of Abacavir hypersensitivity syndrome (AHS) include fever, skin rash, fatigue, gastrointestinal symptoms such as nausea, vomiting, diarrhea or abdominal pain, and respiratory symptoms such as pharyngitis, dyspnea or cough.
HLA-B is a part of the MHC class I antigen-presenting receptor (also called the human leukocyte antigen) system and distinguishes cells between self and non-self for the purposes of the immune system. Hypersensitivity to Abacavir is strongly associated with the HLA-B/*57:01 allele. The mechanism is related to drug-specific activation of T lymphocyte killer cells. HLA-B57 genotyping identifies persons at high risk of developing Abacavir hypersentitivity and the FDA has advised screening for this allele prior to drug therapy.
- Risk assessment for Abacavir therapy/hypersensitivity
- Therapy selection and management
Positive:
- HLA-B*57:01 heterozygous or homozygous indicates significantly increased risk for abacavir hypersensitivity
- Avoidance or discontinuation of abacavir drug is recommended
Negative
- HLA-B*57:01 not detected
- Predicts no increased risk for abacavir hypersensitivity
Negative for HLA-B*57:01 (HLA-B*5701 Not Detected)
Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probe (SSO), Polymerase Chain Reaction (PCR)/Sequence Specific Primer Extension, Sanger sequencing.
Whole blood (ACD yellow top tube is preferred, EDTA lavender top tube also accepted).
Stability
- Ambient: 5 days
- Refrigerated: 7 days
HIV genotyping, HIV phenotyping, HIV viral load, Liver Profile (to monitor safety of the drug), CBC (to monitor safety of the drug), Comprehensive Metabolic Panel (to monitor safety of the drug).
5-14 days.
- NEJM. 2008;358:568–579. [PMID: 18256392]
- Curr Opin Allergy Clin Immunol. 2007;7:324–330. [PMID: 17620824]
- Lancet. 2002;359:1121–1122. [PMID: 11943262]
- Lancet. 2002;359:727–732. [PMID: 11888582]
- Pharmacotherapy. 2013 Jul;33(7):765-75. [PMID: 23649914]
- http://www.fda.gov/cder/drug/InfoSheets/HCP/abacavirHCP.htm FDA abacavir alert web access July 29, 2008